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FOLLOW-UP AND COMPARISON WITH GENERAL POPULATION NORMS
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OBJECTIVES: The incidence of prostate cancer has increased during the last two
decades. Part of this increase has been attributed to prostate specific antigen (PSA)
testing. As a consequence of testing many patients enter treatment at an early
stage of the disease. This might be reflected in their health-related quality of life.
METHODS: An ongoing observational follow-up study using the 15D generic
health-related quality of life (HRQoL) instrument. Patients are asked to fill in the
HRQoL questionnaire at baseline and 3, 6 and 12 months after entering treatment,
and results are compared with those of an age-standardized general population
sample. RESULTS: So far, 587 patients (mean age 66 years) have been assessed at
baseline and 336 have completed the one-year follow-up. The mean HRQoL score
(on a 0-1 scale) of the patients at baseline was statistically significantly better than
that of the general population (0.904 vs. 0.874, p 0.001). Furthermore, the patients
were statistically significantly better off than the population on 9 of the 15 dimen-
sions of the HRQoL instrument. Only the dimensions of elimination (i.e. urinat-
ing)(p  0.001) and sexual function (p  0.05) showed statistically significantly
worse levels in the patients than in the general population. In patients having
completed the one-year follow-up, the total HRQoL score fell from 0.913 to 0.886 (p
 0.001). The greatest deterioration was seen in sexual activity (p  0.001). By
contrast, elimination did not change in a statistically significant manner during
follow-up. CONCLUSIONS: The HRQoL of patients entering treatment is surpris-
ingly good. Although HRQoL of the patients showed slight deterioration during
follow-up, patients were on many of the dimensions of the 15D instrument one
year after diagnosis still better off than the general population. The only clear
exception was sexual activity which showed marked deterioration in the patients
during follow-up.
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OBJECTIVES: To examine the measurement properties of and comparability be-
tween the English and Chinese versions of the Functional Assessment of Cancer
Therapy - Breast (FACT-B) in Singaporean breast cancer patients. METHODS: This
is an observational study of 271 patients. Known-group validity of FACT-B total
score and Trial Outcome Index (TOI) were assessed in relation to performance
status, evidence of disease and treatment status cross-sectionally; responsiveness
to change was assessed in relation to change in performance status longitudinally.
Internal consistency and test-retest reliability were evaluated. Factor analyses
were performed to examine the factor structure of the FACT-General which con-
sisted of the first four subscales of FACT-B, and the breast cancer subscale (BCS).
Multiple regression analyses were performed to compare the scores on the two
language versions, adjusting for covariates. RESULTS: The FACT-B total score and
TOI demonstrated known-group validity in differentiating patients with different
clinical status. They showed high internal consistency (Cronbach’s alpha 0.87 to
0.91) and test-retest reliability (intraclass correlation coefficient 0.82 to 0.89). The
English version was responsive to the change in performance status. The Chinese
version was responsive to decline but inconclusive to improvement in perfor-
mance status due to too few such respondents. Four factors identified from FACT-
General corresponded to the four subscales except two items. Three factors were
identified from the BCS, namely psychological distress, feminine satisfaction, and
physical complaints. Two items concerning sexuality had a high item non-re-
sponse rate (50.2% and 14.4%). No practically significant difference was found be-
tween the two language versions despite minor differences in two items.
CONCLUSIONS: The English and Chinese versions of the FACT-B are valid, respon-
sive and reliable instruments in assessing health-related quality of life in Singa-
porean breast cancer patients. Data collected from the two language versions can
be pooled and either version could be used for bilingual patients.
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OBJECTIVES: Although the incidence of thyroid carcinoma is constantly rising,
little is known about the issue of quality of life (QOL) in this patient group. A
ten-year survival rate of 90% and therapeutic options with minor side-effects may
blind physicians and researchers to the fact that patients not only have to face a
cancer diagnosis and fear of recurrence, but are struggling with endocrine prob-
lems, severely affecting their QOL. Therefore, in the present study we aim at lon-
gitudinally assessing QOL in thyroid cancer patients from the beginning of radio-
nuclide therapy onward. A further aim is to implement a computer-based
QOL-monitoring. METHODS: Thyroid cancer patients admitted for inpatient stay
(either for radionuclide therapy or aftercare) at the University Clinic for Nuclear
Medicine were consecutively included in the study. Following an aftercare visit at
6 months after therapy, patients are monitored on an annual basis. QOL was as-
sessed with the widely used EORTC Quality of Life Questionnaire (QLQ-C30) at each
hospital visit. Data analysis was done using mixed linear models. RESULTS: Data
from 55 patients (63.4% female, age 45.8/16.8) with a total of 236 measurements
were analyzed. Patients showed significantly (0.05) more severe impairments at
the time point of therapy compared to aftercare visits on several QOL dimensions
(functioning: physical, social, role, emotional; symptoms: fatigue, pain, dyspnea).
On the majority of these dimensions females reported significantly more symp-
toms than males. During early aftercare QOL scores returned to general population
levels. Computer-based QOL-monitoring is being currently implemented. Results
will be showed at the conference. CONCLUSIONS: The results show that the QOL of
thyroid cancer patients is diminished during the time of therapy until early after-
care. To alleviate symptom burden the need for medical or psychosocial interven-
tion needs to be identified timely. This can be done using computer-based QOL-
monitoring, allowing immediate action.
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OBJECTIVES: Head and neck cancer can profoundly affect patients’ quality of life
(QoL) but disease-specific QoL instruments alone may not give an appropriate view
of this multidimensional disease. METHODS: An observational follow-up study
using the 15D standardized, self-administered generic health-related quality of life
(HRQoL) instrument which the patients were asked to fill in at baseline and at 3, 6
and 12 months after entering treatment. Results of 91 patients having so far com-
pleted one-year follow-up were compared with those obtained from age-and gen-
der-standardized representative sample of the general population. RESULTS:
Mean HRQoL score (on a 0-1 scale) of the patients entering treatment (mean age 62
years, 60 % men) was only slightly worse than that of the general population (0.870
vs. 0.888, p0.059). However, on the dimensions of depression, distress and sexual
activity the patients were at baseline clearly worse off than the general population
(p0.001) Lesser impairment was seen on the dimensions of sleeping, eating and
speech (p0.01). During the one-year follow-up the total HRQoL score showed
slight deterioration from 0.870 to 0.845 (p0.019). The most marked worsening was
seen on the dimensions of speech (p0.001) and eating (p0.01). By contrast, the
dimensions of distress (p0.01) and depression (p  0.05) showed at the one-year
follow-up some improvement compared to baseline.CONCLUSIONS:The HRQoL of
patients entering treatment is fairly good in comparison to that of the general
population. Nevertheless patients appear to suffer from significant depression,
distress and impaired sexual activity which should be taken into account in the
treatment of head and neck cancer patients. During the follow-up the overall
HRQoL score showed, despite of intensive treatment, only slight deterioration. The
dimensions of eating and speech were negatively affected by treatment but the
dimensions reflecting psychological well-being (distress and depression) showed
some improvement compared to baseline.
PCN148
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OBJECTIVES: In order to construct a cost-utility model, evidence is required of the
Health Related Quality of Life (HRQL) experienced by patients suffering from the
disease. In advanced melanoma, data is available from a vignette-based standard
gamble (SG) study in the general population. However, patient reported HRQL data
was also captured in the ipilimumab pivotal trial, MDX010-20, using the EORTC
QLQ-C30 and the SF-36 generic health surveys. METHODS: Patient level EORTC
data from the MDX010-20 trial was mapped using the EORTC-8D algorithm to pro-
duce EQ-5D utilities, which were then stratified according to disease progression
(progression-free or post-progression), and treatment arm. This process was re-
peated with the patient level SF-36 data based upon a nonparametric Bayesian
method to generate SF-6D utility values. The results were then compared with
results generated from the vignette-based study. RESULTS: In the progression free
health state, the SG and EORTC data show a high degree of correlation in utility
(0.77 vs 0.80), with the SF-36 value being significantly lower (0.64). In the post-
progression state, comparing to the utility values in the progression free state, the
SG data shows a significant fall of 0.18 (23.4%) in expected utility, however, this is
not mirrored in patient data, where there is a fall of 0.04 (4.7%) in the EORTC data,
and 0.02 (3.3%) in the SF-36 data, showing patients do not appear to have a signif-
icantly worsened HRQL with disease progression. CONCLUSIONS: Despite the lim-
itations of the study in both patient numbers, and being limited to a single disease,
investigators should be aware different measures administered to the same pa-
tients may yield differing results. Equally further research should be carried out on
HRQL associated with disease progression from the viewpoint of both patients and
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the general public, as it is possible there are differences in the valuation of states
close to death.
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OBJECTIVES:Health-related quality of life is an important issue in the treatment of
breast cancer (BC) and health-state utility values (HSUVs) are essential for cost-
utility analysis. The aim of the study was to identify published values for common
health states for breast cancer and to determine pooled estimates of HSUVs for
each identifiable health state. METHODS: A systematic review of HSUVs for condi-
tions relating to BC was undertaken. Thirteen databases were searched in March
2009. HSUVs were allocated to six categories: screening related states, preventative
states, adverse events in breast cancer and its treatment, non-specific breast can-
cer, early breast cancer (EBC) states and metastatic breast cancer (MBC) states.
Where appropriate meta analysis was used to provide utilities based on combining
all available evidence. Mean utility estimates were pooled using ordinary least
squares with utilities clustered within study group and weighted by both number
of respondents and inverse of the variance of each utility. Regressions included
controls for disease state, utility assessment method and other features of study
design. RESULTS: Forty-nine articles were identified, providing 476 unique utility
values. From these, 117 values for MBC and 230 values for EBC were extracted and
analysed by regression analysis. Utilities were found to vary significantly by valu-
ation method (e.g. in EBC standard gamble had higher valuations than TTO and
EQ-5D), and source of values. For MBC values significantly varied in expected di-
rection by severity of condition, treatment and side-effects. CONCLUSIONS: De-
spite the numerous studies it was not feasible to generate a definitive list of HSUVs
that could be used in future economic evaluations, due to the complexity of the
health states involved and the variety of methods used to obtain values. Future
research into quality of life in BC should make greater use of validated generic
preference-based measures for which public preferences exist.
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OBJECTIVES: The objective of this analysis was to assess patients’ willingness to
pay (WTP) for a reduction in risk of breast cancer treatment side effects.METHODS:
A survey was developed using continent valuation processes to assess the WTP for
a reduction in side effects. The survey asked female MBC patients to provide the
amount they were willing to pay for a 25%, 50% and 100% reduction in risk of the
following side effects: diarrhea/dehydration, hair loss, fatigue, nausea, neutrope-
nia/febrile neutropenia, pain and tingling in hands and feet. Patients were also
asked to select the side effect they would pay the most to avoid. Demographic
information such as age, race/ethnicity, region, employment status, insurance
type, and treatment regimen was also collected. RESULTS:A total of 202 metastatic
breast cancer patients completed the survey. The majority of respondents were
white, married, over the age of 51, and well educated. Most respondents had pri-
vate insurance (67%) or Medicare (24%). Of those who reported paying out of pocket
for their last treatment (58%), the average payment was $459. For a 25%, 50%, and
100% reduction in the risk of side effects, respondents were willing to pay an extra
$1886, $3837 and $7794, respectively. Hair loss (28%), pain (17%) and nausea (15%)
were selected most often as the side effect respondents would pay the most to
avoid. CONCLUSIONS: Patients with MBC highly value reduction in treatment side
effects and are WTP 4.2 times more for a treatment devoid of side effects over a
treatment with a 25% reduction in the risk of side effects. Additional research is
warranted to quantify WTP for specific side effects.
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OBJECTIVES: As outcomes research is being used to inform the decision-maker
about continuation of reimbursement of expensive hospital drugs in the The Neth-
erlands since 2006, this type of research is becoming more important. Our study
started before 2006 and aimed to evaluate therapies in daily clinical practice and
their costs and outcomes. This study gives an indication of the challenges that may
arise from the design of outcomes research.METHODS:An observational follow-up
study was performed including 160 patients with chronic lymphocytic leukemia
(CLL). Data collection on treatment, costs and outcome was performed in 19 Dutch
hospitals using medical records. RESULTS: Patients diagnosed between 1999 and
2003 were included and followed during 6.4 years on average. The mean age was 63
years (range: 30-86). 20% received one therapy-line, 12% two and 24% received three
or more therapy-lines. Most patients received chlorambucil (87%) as first therapy
and the second line was dominated by fludarabine (46%). However, therapies from
the third line onwards varied extensively. Due to the development of new medi-
cines like monoclonal antibodies, the treatment sequence changed in the more
recently diagnosed patients. As a consequence of the relatively low incidence of
CLL and the variety in therapy, the number of patients with comparable therapies
was small. CONCLUSIONS:Management of CLL varied strongly especially after the
second therapy-line. This may be caused by the introduction of monoclonal anti-
bodies as first and second line treatment during the study period. Additionally, a
comparison of alternative therapies was hampered due to relative small number of
patients. Consequently, modeling studies or patient registrations might be neces-
sary to obtain valid information about cost-effectiveness of new expensive inpa-
tient medicines in (chronic) diseases with a low incidence rate and a highly variable
or changing management strategy.
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CAN BREAST CANCER RISK PREDICTION REDUCE THE RISKS OF FALSE
NEGATIVE AND FALSE POSITIVE SCREENING MAMMOGRAMS?
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OBJECTIVES: Controversy continues about screening mammography, partially be-
cause of risks involved. Pre-test breast cancer risk prediction may improve positive
and negative predictive value of screening mammography, particularly among
women who have an abnormal screening mammogram. METHODS: We modeled
one-year breast cancer risk in women with abnormal screening mammograms
(BI-RADS3, BI-RADS4) by combining estimates of pre-test breast cancer risk based
upon established risk factors, 12 validated SNPs and the average probability of
cancer given BI-RADS category. We examined the degree to which the incorpora-
tion of pre-test breast cancer risk would reclassify women from current recom-
mendations for short-term follow up of BI-RADS3 and biopsy of BI-RADS4 using
biopsy thresholds of 1, 2 and 3% probability of breast cancer. RESULTS: Women
with BI-RADS3 in the lowest 5% of pre-test breast cancer risk had a one-year aver-
age breast cancer risk of 0.24% compared to 2.7% for women in the highest 5% of
pre-test risk. Women with BI-RADS4 in the lowest 5% of pre-test risk had a one-year
average breast cancer risk of 4.9% compared to 39.8% for women in the highest 5%
of pre-test risk. Incorporating BI-RADS 4 subclassifications increased the risk dis-
crimination, women with BI-RADS 4A in the lowest 5% of pre-test probability had a
one-year breast cancer risk of 1.4%. Using a biopsy risk threshold of 2%, 8% of
women with a BI-RADS3 had a post-test risk above the threshold for biopsy and 7%
of women with BI-RADS4A had a post-test risk below the threshold.
CONCLUSIONS: Although incorporation of pre-test risk estimates changes deci-
sions about management of abnormal mammograms for a relatively small propor-
tion of women, the public health impact could be significant given the incidence of
abnormal mammograms. Prospective studies are needed to determine effective-
ness of breast cancer risk prediction in improving the positive and negative pre-
dictive value of mammography screening.
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OBJECTIVES: Although cancer morbidity is lower than cardiovascular or metabolic
diseases, it is still the second leading cause of mortality and also the major eco-
nomic problem due to high cost of treatment. According to estimations by the
Karolinska Institutet and Stockholm School of Economics, the direct costs of caring
for cancer patients are approximately 6.5% of total healthcare costs. The aim of this
study was to estimate cost of hospital care in population of patients with neo-
plasms in 2009. METHODS: We used National Health Fund (NHF) statistics on Di-
agnosis-Related Groups (DRGs) attrition in 2009 year. Precise, in respect to ICD-10
diagnosis, NHF statistics cover 85% of all data. We identified data only for malig-
nant neoplasms (C00-C97), in situ neoplasms (D00-D09) and neoplasms of uncer-
tain or unknown behavior (D37-D48). Values are presented in Euro (exchange rate:
1 EUR4.00 PLN). RESULTS: Cost of hospital care in population of patients with
neoplasms was estimated to amount of 246.3 million EUR (289.7 million EUR when
correction for 85% statistics cover will be applied). The highest costs of hospital
care were related to malignant neoplasm of bronchus and lung (34.3 million EUR)
followed by malignant neoplasm of bladder (26.5 million EUR), and malignant neo-
plasm of colon (22.8 million EUR). Given the number of cancer patients in Poland
which is estimated to be 270 thousands, cost of hospital care per cancer patient per
year would be approximately 1073 EUR. However apart from DRGs, cost of hospital
care in population of patients with neoplasms includes also separately contracted
chemotherapy (374.3 million EUR) and some Therapeutics Programs with a new
drugs such as trastuzumab in breast cancer (46.1 million EUR) . CONCLUSIONS:
Cost of hospital care in population of cancer patients is substantial and account for
over 11.5% of all costs of hospital care in Poland in 2009.
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DISCUSSING THE INTRODUCTION OF NATIONAL SCREENING PROGRAMS IN
GREECE: A DELPHI STUDY
Skroumpelos A, Pavi E, Kyriopoulos J
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OBJECTIVES: In the absence of national screening programs (NSP) for adults in
Greece, the aim of this study was to examine experts’ views and recommendations
on a predefined set of NSPs METHODS: A systematic review was conducted to
identify those screening programs that best meet the criteria of clinical effective-
ness and cost efficiency. The programs identified were set for evaluation in a multi-
professional expert panel which completed a structured questionnaire in three
rounds, using the Delphi method. Experts’ agreement was investigated as well as
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